Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SCN1A | P35498 | 4/20 | 0.48 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31123666 | 0.87 | ALDH1A1 (0.66) | ALDH1A1LMNAKMT2ASCN1ASCN2A | |
| SCHEMBL4068457 | 0.87 | ALDH1A1 (0.66) | ALDH1A1LMNAKMT2ASCN1ASCN2A | |
| SCHEMBL10360804 | 0.85 | ALDH1A1 (0.77) | ALDH1A1LMNAKMT2APOLBKDM4E | |
| SCHEMBL28095120 | 0.82 | ALDH1A1 (0.52) | ALDH1A1LMNAKDRKMT2APOLB | |
| SCHEMBL21056760 | 0.82 | KDM4E (0.51) | ALDH1A1LMNAKMT2AKDM4ETSHR | |
| SCHEMBL29373730 | 0.81 | KDR (0.57) | ALDH1A1LMNAKDRADRB2KDM4E | |
| SCHEMBL13604313 | 0.80 | PLA2G2A (0.49) | ALDH1A1LMNAKDRKMT2APOLB | |
| SCHEMBL13604312 | 0.80 | KDR (0.64) | ALDH1A1LMNAKDRADRB2KDM4E | |
| SCHEMBL4354269 | 0.80 | KDR (0.56) | ALDH1A1LMNAKDRKMT2AADRB2 | |
| SCHEMBL17429661 | 0.79 | ALDH1A1 (0.59) | ALDH1A1LMNAKMT2ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | SCHERING AG (DE) | 2011-01-13 | — | — | US | disclosed |
| CN-1285578-C | Substituted benzoic acid amides and their use in inhibiting angiogenesis | SCHERING AG (DE) | 2006-11-22 | — | — | CN | disclosed |
| CN-1426396-A | Substituted benzoic acid amides and use for inhibition of angiogenesis thereof | SCHERING AG (DE) | 2003-06-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | VEGFA, EGLN2, HIF1AN | ALDH1A1 155/4885LMNA 3771/4885KDR 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.